FAMICEF
Cefuroxime Axetil
ANTI-INFECTIVE
INDICATION
Upper respiratory tract infections: Ear, nose and throat infections such as otitis media, sinusitis, tonsillitis, and pharyngitis.
Lower respiratory tract infection: Acute bronchitis, acute exacerbations of chronic bronchitis and pneumonia.
Skin and soft tissue infections: Furunculosis, pyoderma and impetigo.
Genito-urinary tract infections: Pyelonephritis, urethritis and cystitis.
Multidrug-resistant typhoid fever.
Gonorrhoea: Acute uncomplicated gonococcal urethritis and cervicitis.
Early Lyme Disease and subsequent prevention of late Lyme Disease.
DOSAGE AND ADMINISTRATION
Infection | Dosage | Duration | |||
Adolescents and Adults (13 years and older) | |||||
Pharyngitis / tonsillitis | 250 mg b.i.d. | 10 days | |||
Acute bacterial maxillary sinusitis | 250 mg b.i.d. | 10 days | |||
Acute bacterial exacerbations of chronic bronchitis | 250 or 500 mg b.i.d. | 10 days | |||
Secondary bacterial infections of acute bronchitis | 250 or 500 mg b.i.d. | 5 – 10 days | |||
Uncomplicated skin and skin-structure infections | 250 or 500 mg b.i.d. | 10 days | |||
Uncomplicated urinary tract infections | 125 or 250 mg b.i.d. | 7 – 10 days | |||
Uncomplicated gonorrhoea | 1,000 mg once | Single dose | |||
Early Lyme Disease | 500 mg b.i.d | 20 days | |||
Pediatric Patients (who can swallow tablets whole) | |||||
Acute otitis media | 250 mg b.i.d. | 10 days | |||
Acute bacterial maxillary sinusitis | 250 mg b.i.d. | 10 days | |||
Infection | Dosage (divided b.i.d.) | Maximum Dose | Duration | ||
Pediatric Patients (3 months to 12 years) | |||||
Pharyngitis / tonsillitis | 20 mg/kg/day | 500 mg | 10 days | ||
Acute otitis media | 30 mg/kg/day | 1,000 mg | 10 days | ||
Acute bacterial maxillary sinusitis | 30 mg/kg/day | 1,000 mg | 10 days | ||
Impetigo | 30 mg/kg/day | 1,000 mg | 10 days | ||
Injection : Adult : 750 mg three times daily by IM / IV injection.
Infants and Children : 30 – 100 mg / kg /day given in 3 or 4 equally divided doses. A dose of 60 mg / kg /day is appropriate for most infections.
Neonate : 30 – 100 mg / kg / day given in 2 or 3 equally divided doses.
Surgical prophylaxis : 1.5 gm by IV injection at induction of anaesthesia. Thereafter, give 750 mg IM / IV every 8 hours when the procedure is prolonged.
Sequential therapy in adults : Pneumonia : 1.5 gm IV injection three times or twice daily for 2 – 3 days, followed by 500 mg twice daily (oral) for 7 – 10 days. Acute exacerbations of chronic bronchitis : 750 mg three times or twice daily (IM / IV injection) for 2 – 3 days, followed by 500 mg twice daily (oral) for 5 – 10 days. (Duration of both parenteral and oral therapy is determined by the severity of the infections and the clinical status of the patient).
Other recommendations : In Gonorrhoea : Adults : 1.5 gm as a single dose (as 2 X 750 mg injections given intramuscularly with different sites, e.g. each buttock). In Meningitis : Adults : 3 gm IV injection three times daily.
Children (above 3 months of age) : 200 – 240 mg / kg /day by IV injection in 3 or 4 divided doses reduced to 100 mg / kg / day after 3 days or on clinical improvement.
Neonates : 100 mg / kg / day by IV injection reduced to 50 mg / kg / day.
In bone and joint infections : Adults : 1.5 gm injection 3 times daily.
Children (above 3 months of age) : 150 mg / kg / day (not to exceed the maximum adult dose) in equally divided doses every 8 hours.
COMPOSITION
Famicef® 250 Tablet : Cefuroxime Axetil USP 250 mg.
Famicef® 500 Tablet : Cefuroxime Axetil USP 500 mg.
Famicef® Powder for Suspension : Cefuroxime Axetil USP 125 mg /5 ml.
Famicef® 750 mg IM / IV Injection : Cefuroxime Sodium USP sterile powder equivalent to Cefuroxime 750 mg / vial.
Famicef® 1.5 g IV injection : Cefuroxime Sodium USP sterile powder equivalent to Cefuroxime 1.5 g / vial.